We are the company that will achieve productive aging worldwide,delivering wellness science based on research evidence.
We are the company that will achieve productive aging worldwide,delivering wellness science based on research evidence.Shinkowa Pharmaceutical, Co. Ltd. (Main office: Tokyo, Japan; CEO: Megumi Tanaka) was the first company in the world to commercialize nutraceuticals (that is, health food supported by scientific evidence) and cosmetics with β- nicotinamide mononucleotide (NMN), a substance that is generally considered to contribute to healthy lifespan. We conducted the world’s first NMN clinical research on humans and have established a reputation as pioneers in the field of NMN bio-ventures by launching steadily a range of products based on science. We take care of them all the way from the research phase to the commercialization of the final product.
What’s more, purity tests carried out by the Institute for Research on Productive Aging (IRPA (1)) guarantee our NMN has an amazing purity degree of over 99%. Our NMN is also highly stable, and its safety has been confirmed in both humans and rodents by the Graduate School of Medical and Dental Health Sciences, National University of Hiroshima. Only two companies in the world can offer such NMN nutraceuticals and cosmetics, and we are one of them. Our goal is contributing to society by improving our quality of life based on science.
On September 10th, we will inaugurate our Kobe branch on the 7th floor of the Kobe KIMEC Center Building (Minamimachi, Minatojima, Chuo-ku, Kobe, Japan) near IRPA’s facilities. The Kobe KIMEC Center Building is a 24-hour-operation intelligent building that gathers 300 medical research institutions and companies.
Our Kobe branch office will continue to work more closely with IRPA in terms of joint research and patent acquisition.
In the future, we plan to further progress our joint research with IRPA and several other research institutes and expand into the pharmaceutical sector.
Address: 7th floor, Kobe KIMEC Center Building, 1-5-2 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo Prefecture, Japan.
Phone: +81 78-515-6963. Fax: +0081 78-515-6992
Surface area: 81.8 m2
(1) IRPA was established with the goal of realizing a society with a long, healthy lifespan through the promotion of the world’s most advanced research on lifespan and aging as well as the implementation of its results. Please visit IRPA’s web: https://www.irpa.ne.jp/
In July 2020, we welcomed Professor Yoichi Nabeshima as our medical advisor and Professor Takashi Hiramatsu as our scientific advisor.
Medical Advisor: Yoichi Nabeshima, M. D.
– Director of Foundation for Biomedical Research and Innovation at Kobe.
– Professor Emeritus of Kyoto University.
– Project Fellow of Center for Research and Development Strategy (JST/CRDS).
– Chairman, Productive Aging Research Organization (IRPA).
Scientific Advisor: Ryuji Hiramatsu, Ph.D.
– Executive coordinator, Center for Cluster Development and Coordination, Foundation for Biomedical Research and Innovation at Kobe.
– Director of Department of Industry-Academia Collaborative Research, Institute of Biomedical Research and Innovation.
– Japan Agency for Medical Research and Development (AMED), CiCLE Program Officer (PO).
Doctor of Agriculture.
Executive Board Member, Institute for Research on Productive Aging (IRPA).
ABOUT SHINKOWA PHARMACEUTICAL’S NMN
Our NMN is highly stable, and its safety has been confirmed in both humans and rodents. Only two companies in the world can offer such high-quality, high-purity NMN nutraceuticals and cosmetics, and we are one of them.
The Institute for Research on Productive Aging (IRPA) carried out two different test methods (LC-UV (1) and NMR (2)), on four NMN samples from as many companies, and the only NMN with at least 99% purity was Shinkowa’s NMN. These results indicate that the NMN from the other three companies may contain more impurities, such as water or heavy metals.
(1): High performance liquid chromatography- UV absorption spectroscopy
(2): Nuclear magnetic resonance spectroscopy
Please visit IRPA’s web: https://www.irpa.ne.jp/
More about Shinkowa’s NMN here: https://shinkowapharma.com/en/information/603/
– We have confirmed the existence of malicious sites that copy and paste pictures and explanatory texts directly from our own website and offer our products illegally. To certify that the products you receive are genuine, you will start finding on our products authentication holograms from July 15, 2020. While we would like to extend this security measure to all our products as soon as possible, please note that some of the products acquired through our Mirai Lab and Mirai Dakara stores on Amazon will not display the holograms yet. We would like to thank you in advance for your understanding.
・Please note that there are products on the market that do not contain NMN, even though “NMN” is displayed on their labels, and also products whose safety has not been confirmed.
■ What is NMN (β-nicotinamide mononucleotide)?
NMN (β-nicotinamide mononucleotide) is a safe substance made from vitamin B3 in the cells of living organisms, and it is present in all creatures. It is found in relatively high amount in foods such as broccoli and edamame beans, but we cannot replenish our NMN body stock with our daily ingest of food. More and more pieces of evidence suggest health improvement by taking purer NMN. For example, it has been reported improvement on cases of geriatric obesity, diabetes, fatty liver, hyperlipidemia, decreased metabolic muscle capacity, decreased bone density, decreased activity, and many others.
While research is ongoing around the world to find out more about its mechanisms, it has been discovered so far that NMN is converted to another substance called NAD＋and acts on the life support center of the hypothalamus, which in turn acts on skeletal muscle, viscera, cells, mitochondria, blood vessels, nerves and response proteins (signal substances) among others, all essential for sustaining life.
Taking NAD＋directly will not cause the same effects as taking NMN. The reason is that when NAD＋is ingested, most of it is broken up in the digestive tract. In addition, NAD＋does not pass through the brain-blood barrier or enter the cells easily. Direct administration of NAD＋ into blood vessels may cause abnormal glucose metabolism, a reaction similar to diabetes. For all these reasons, it is important to take NMN, not NAD＋.
Compared to NAD＋, the absorption rate of NMN into the cells is considered higher, so it should be extremely suitable for intracellular NAD+ deficiency.
In the human epidermis, regeneration (the physiological process of discarding old, deteriorated cells and replacing them with new cells) happens continuously and proper gene expression in the cells is essential for this process. As NMN enters the cells and is converted to NAD+, it is expected to eliminate problems caused by aging: the lack of NAD+, the abnormal gene expression and the disruption of physiological processes, such as cell regeneration, among others.
■RESEARCH ACHIEVEMENTS OF SHINKOWA PHARMACEUTICAL
This clinical research, which focuses on the effects of NMN after oral administration, will be conducted by Shin-Ichiro Imai, M.D., Ph. D. (Washington University in St. Louis (Missouri), School of Medicine, Department of Developmental Biology/ Department of Medicine (joint)) and Samuel Klein (William H. Danforth Professor of Medicine and Nutritional Science Chief, Division of Geriatrics and Nutritional Science, Director of the Center for Applied Research Sciences). Shinkowa Pharmaceutical’s NMN is highly considered, so it was officially adopted as the NMN product used for this clinical research.
For more details: https://shinkowapharma.com/en/information/458/
We will also announce the joint research with IRPA and Meiji HD as soon as we settle the specific details.
IRPA’s web: https://www.irpa.ne.jp/
In November 2018, we concluded an agreement with the non-profit organization The Systems Biology Institute (CEO: Dr. Hiroaki Kitano) to carry out research that aims to elucidate the mechanisms of action of NMN. This study is called ” Elucidation of Intracellular Mechanism of NMN by Multi-Omics Analysis”.
Click here for details: https://shinkowapharma.com/en/information/202/
In June 2019, we opened and started operating our in-house research laboratory in Nihonbashi, Tokyo, Japan, with the aim to further increase the scientific basis of NMN. Currently, we are conducting research in our Life Science Lab with the goal of demonstrating scientifically the effects of NMN, a safe organic substance, to strengthen immunity and help prevent and treat infectious diseases, as one of the measures taken against infectious diseases, including the COVID-19 (new coronavirus).
For more details: https://shinkowapharma.com/en/information/520/
In addition to the projects stated above, we are engaged in other activities, including research in our in-house laboratory and joint research with Japanese universities.
Shinkowa Pharmaceutical Co., Ltd.